Advanced

Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease

Brundin, Patrik LU ; Pogarell, O; Hagell, Peter LU ; Piccini, P; Widner, Håkan LU ; Schrag, A; Kupsch, A; Crabb, L; Odin, Per and Gustavii, Björn, et al. (2000) In Brain 123. p.1380-1390
Abstract
Five parkinsonian patients were transplanted bilaterally into the putamen and caudate nucleus with human embryonic mesencephalic tissue from between seven and nine donors. To increase graft survival, the lipid peroxidation inhibitor tirilazad mesylate was administered to the tissue before implantation and intravenously to the patients for 3 days thereafter. During the second postoperative year, the mean daily L-dopa dose was reduced by 54% and the UPDRS (Unified Parkinson's Disease Rating Scale) motor score in 'off' phase was reduced by a mean of 40%. At 10-23 months after grafting, PET showed a mean 61% increase of 6-L-[(18)F]fluorodopa uptake in the putamen, and 24% increase in the caudate nucleus, compared with preoperative values. No... (More)
Five parkinsonian patients were transplanted bilaterally into the putamen and caudate nucleus with human embryonic mesencephalic tissue from between seven and nine donors. To increase graft survival, the lipid peroxidation inhibitor tirilazad mesylate was administered to the tissue before implantation and intravenously to the patients for 3 days thereafter. During the second postoperative year, the mean daily L-dopa dose was reduced by 54% and the UPDRS (Unified Parkinson's Disease Rating Scale) motor score in 'off' phase was reduced by a mean of 40%. At 10-23 months after grafting, PET showed a mean 61% increase of 6-L-[(18)F]fluorodopa uptake in the putamen, and 24% increase in the caudate nucleus, compared with preoperative values. No obvious differences in the pattern of motor recovery were observed between these and other previously studied cases with putamen grafts alone. The amount of mesencephalic tissue implanted in each putamen and caudate nucleus was 42 and 50% lower, respectively, compared with previously transplanted patients from our centre. Despite this reduction in grafted tissue, the magnitudes of symptomatic relief and graft survival were very similar. These findings suggest that tirilazad mesylate may improve survival of grafted dopamine neurons in patients, which is in agreement with observations in experimental animals. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
neural transplantation, Parkinson's disease, lazaroid, dopamine, positron emission tomography
in
Brain
volume
123
pages
1380 - 1390
publisher
Oxford University Press
external identifiers
  • pmid:10869050
ISSN
1460-2156
language
English
LU publication?
yes
id
ae157cc5-30f3-4687-af44-ac5d20d9ae89 (old id 1117002)
alternative location
http://brain.oxfordjournals.org/cgi/content/full/123/7/1380
date added to LUP
2008-07-02 14:46:17
date last changed
2016-04-15 18:51:55
@article{ae157cc5-30f3-4687-af44-ac5d20d9ae89,
  abstract     = {Five parkinsonian patients were transplanted bilaterally into the putamen and caudate nucleus with human embryonic mesencephalic tissue from between seven and nine donors. To increase graft survival, the lipid peroxidation inhibitor tirilazad mesylate was administered to the tissue before implantation and intravenously to the patients for 3 days thereafter. During the second postoperative year, the mean daily L-dopa dose was reduced by 54% and the UPDRS (Unified Parkinson's Disease Rating Scale) motor score in 'off' phase was reduced by a mean of 40%. At 10-23 months after grafting, PET showed a mean 61% increase of 6-L-[(18)F]fluorodopa uptake in the putamen, and 24% increase in the caudate nucleus, compared with preoperative values. No obvious differences in the pattern of motor recovery were observed between these and other previously studied cases with putamen grafts alone. The amount of mesencephalic tissue implanted in each putamen and caudate nucleus was 42 and 50% lower, respectively, compared with previously transplanted patients from our centre. Despite this reduction in grafted tissue, the magnitudes of symptomatic relief and graft survival were very similar. These findings suggest that tirilazad mesylate may improve survival of grafted dopamine neurons in patients, which is in agreement with observations in experimental animals.},
  author       = {Brundin, Patrik and Pogarell, O and Hagell, Peter and Piccini, P and Widner, Håkan and Schrag, A and Kupsch, A and Crabb, L and Odin, Per and Gustavii, Björn and Björklund, Anders and Brooks, D J and Marsden, C D and Oertel, W H and Quinn, N P and Rehncrona, Stig and Lindvall, Olle},
  issn         = {1460-2156},
  keyword      = {neural transplantation,Parkinson's disease,lazaroid,dopamine,positron emission tomography},
  language     = {eng},
  pages        = {1380--1390},
  publisher    = {Oxford University Press},
  series       = {Brain},
  title        = {Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease},
  volume       = {123},
  year         = {2000},
}